Josh Simmons, MD
Hematology & Oncology · Thomasville, GANPI 1942461132
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in GA, where the typical reported total is $4,479.
Across 168 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$318
- E.r. Squibb & Sons, L.L.C.$275
- Novartis$214
- Takeda Pharmaceuticals U.S.A., Inc.$180
- Stryker$173
- Johnson & Johnson$163
- plus $2K from 35 others
Across 179 payments — averaging $22,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.1M
- Merck$406K
- E.r. Squibb & Sons, L.L.C.$186K
- Incyte Corporation$82K
- Sanofi US Services Inc.$82K
- Regeneron$38K
- plus $140K from 7 others
What the payments were for
- Food & beverage$2,99993%
- Education$2247%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $318 |
| E.r. Squibb & Sons, L.L.C. | 18 | $275 |
| Novartis | 12 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $180 |
| Stryker | 1 | $173 |
| Johnson & Johnson(2 entities) | 10 | $163 |
| Intuitive Surgical | 1 | $132 |
| Pfizer | 8 | $129 |
| Gilead | 8 | $128 |
| Genentech USA, Inc. | 7 | $127 |
| GSK | 7 | $126 |
| Eisai Inc. | 6 | $121 |
| Seagen Inc. | 6 | $110 |
| Merck | 6 | $106 |
| Sanofi | 4 | $79 |
| Veran Medical Technologies, Inc. | 1 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| AstraZeneca | 4 | $64 |
| Lilly USA, LLC | 3 | $57 |
| Myriad Genetic Laboratories, Inc. | 3 | $53 |
| AbbVie | 3 | $44 |
| Rigel Pharmaceuticals, Inc. | 3 | $44 |
| Bristol Myers Squibb | 3 | $44 |
| Exelixis Inc. | 3 | $42 |
| Astellas Pharma US Inc | 2 | $37 |
| Tesaro, Inc. | 2 | $33 |
| Caris MPI, Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Sobi, Inc | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Array Biopharma Inc | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $13 |
| Coherus Oncology, Inc. | 1 | $13 |
| Foundation Medicine, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,223 in reported general payments places this provider in the 45th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 46 | $1,034,014 |
| BrukinsaZanubrutinib | 57 | $775,114 |
| XtandiEnzalutamide | 29 | $405,127 |
| IbrancePalbociclib | 21 | $325,732 |
| NubeqaDarolutamide | 20 | $273,179 |
| Lenalidomide | 18 | $258,736 |
| ErleadaApalutamide | 18 | $258,564 |
| JakafiRuxolitinib Phosphate | 13 | $214,308 |
| EliquisApixaban | 35 | $19,678 |
| Abiraterone Acetate | 28 | $10,961 |
| Letrozole | 100 | $2,710 |
| Anastrozole | 27 | $696 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $625 |
| Hydroxyurea | 21 | $579 |
| Gabapentin | 42 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $275 | $1,034,01446 claims |
| Astellas Pharma US IncXtandi | $37 | $405,12729 claims |
| PfizerIbrance, Eliquis | $129 | $345,40956 claims |
| BayerNubeqa | $17 | $273,17920 claims |
| Johnson & JohnsonErleada | $163 | $258,56418 claims |
| Incyte CorporationJakafi | $22 | $214,30813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Thomasville
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.